产品: p38 MAPK 单克隆 抗体
货号: BF8015
描述: Mouse monoclonal antibody to p38 MAPK
应用: WB IHC
反应: Human, Mouse, Rat
分子量: 43 kDa; 41kD(Calculated).
蛋白号: Q16539

浏览相似产品>>

   规格 价格 库存
 100ul RMB¥ 888 2300 现货

货期: 当天发货

联系销售

产品描述

来源:
Mouse
应用:
WB 1:1000-1:10000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human,Mouse,Rat
克隆:
Monoclonal [AFfirm8015]
特异性:
p38 MAPK Antibody detects endogenous levels of p38 MAPK .
偶联:
Unconjugated.
纯化:
Affinity-chromatography.
保存:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

CSAID Binding Protein 1; CSAID binding protein; CSAID-binding protein; Csaids binding protein; CSBP 1; CSBP 2; CSBP; CSBP1; CSBP2; CSPB1; Cytokine suppressive anti-inflammatory drug-binding protein; EXIP; MAP kinase 14; MAP kinase MXI2; MAP kinase p38 alpha; MAPK 14; MAPK14; MAX interacting protein 2; MAX-interacting protein 2; Mitogen Activated Protein Kinase 14; Mitogen activated protein kinase p38 alpha; Mitogen-activated protein kinase 14; Mitogen-activated protein kinase p38 alpha; MK14_HUMAN; Mxi 2; MXI2; p38 ALPHA; p38; p38 MAP kinase; p38 MAPK; p38 mitogen activated protein kinase; p38ALPHA; p38alpha Exip; PRKM14; PRKM15; RK; SAPK2A;

抗原和靶标

免疫原:

A synthesized peptide derived from human p38 MAPK.

Uniprot:
基因/基因ID:
表达:
Q16539 MK14_HUMAN:

Brain, heart, placenta, pancreas and skeletal muscle. Expressed to a lesser extent in lung, liver and kidney.

序列:
MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES

翻译修饰 - Q16539 作为底物

Site PTM Type Enzyme
S2 Acetylation
S2 Phosphorylation
T7 Phosphorylation
K15 Ubiquitination
T16 Phosphorylation
S28 Phosphorylation
S32 Phosphorylation
K45 Ubiquitination
K53 Acetylation
K54 Ubiquitination
S56 Phosphorylation
S61 Phosphorylation
K66 Ubiquitination
K79 Sumoylation
K79 Ubiquitination
K118 Ubiquitination
K121 Ubiquitination
T123 Phosphorylation P25098 (GRK2)
K139 Ubiquitination
S143 Phosphorylation
K152 Acetylation
K152 Ubiquitination
K165 Ubiquitination
T175 Phosphorylation
T180 Phosphorylation P46734 (MAP2K3) , P52564 (MAP2K6) , P07949 (RET) , P45985 (MAP2K4) , Q99683 (MAP3K5) , O95382 (MAP3K6) , Q16539 (MAPK14)
Y182 Phosphorylation P52564 (MAP2K6) , O95382 (MAP3K6) , P45985 (MAP2K4) , Q16539 (MAPK14) , O14733-2 (MAP2K7) , Q99683 (MAP3K5) , P46734 (MAP2K3) , P07949 (RET)
T185 Phosphorylation
K233 Ubiquitination
T241 Phosphorylation
K248 Ubiquitination
K249 Ubiquitination
R256 Methylation
T263 Phosphorylation
K295 Ubiquitination
Y323 Phosphorylation P06241 (FYN) , P06239 (LCK) , P43403 (ZAP70)
S326 Phosphorylation
K338 Sumoylation
S339 Phosphorylation

翻译修饰 - Q16539 作为激酶

Substrate Site Source
F1D8S2 (NR2A1) S167 Uniprot
O00418 (EEF2K) S396 Uniprot
O15198 (SMAD9) T136 Uniprot
O43255 (SIAH2) S28 Uniprot
O43257 (ZNHIT1) T103 Uniprot
O43521 (BCL2L11) S69 Uniprot
O43524 (FOXO3) S7 Uniprot
O43524 (FOXO3) S12 Uniprot
O43524 (FOXO3) S294 Uniprot
O43524 (FOXO3) S344 Uniprot
O43524 (FOXO3) S425 Uniprot
O60381 (HBP1) S402 Uniprot
O75030 (MITF) S414 Uniprot
O75582 (RPS6KA5) S360 Uniprot
O75582-1 (RPS6KA5) S376 Uniprot
O75582 (RPS6KA5) T581 Uniprot
O75582 (RPS6KA5) T700 Uniprot
O75676 (RPS6KA4) S196 Uniprot
O75676-2 (RPS6KA4) S343 Uniprot
O75676-2 (RPS6KA4) S347 Uniprot
O75676 (RPS6KA4) S360 Uniprot
O75676-2 (RPS6KA4) T562 Uniprot
O75676 (RPS6KA4) T568 Uniprot
O95644 (NFATC1) S172 Uniprot
P00533 (EGFR) T693 Uniprot
P00533 (EGFR) S1039 Uniprot
P00533 (EGFR) T1041 Uniprot
P02511 (CRYAB) S59 Uniprot
P03372 (ESR1) S118 Uniprot
P03372 (ESR1) S294 Uniprot
P03372-1 (ESR1) T311 Uniprot
P04150 (NR3C1) S203 Uniprot
P04150 (NR3C1) S211 Uniprot
P04150 (NR3C1) S226 Uniprot
P04637 (TP53) S15 Uniprot
P04637 (TP53) S33 Uniprot
P04637 (TP53) S46 Uniprot
P04637-1 (TP53) S392 Uniprot
P04792 (HSPB1) S176 Uniprot
P05198 (EIF2S1) S52 Uniprot
P05787-1 (KRT8) S74 Uniprot
P06400 (RB1) S567 Uniprot
P06702 (S100A9) T113 Uniprot
P10275 (AR) S651 Uniprot
P10415 (BCL2) T56 Uniprot
P10415 (BCL2) S87 Uniprot
P10636-8 (MAPT) T50 Uniprot
P10636-8 (MAPT) T69 Uniprot
P10636-8 (MAPT) T153 Uniprot
P10636-8 (MAPT) S202 Uniprot
P10636-8 (MAPT) T205 Uniprot
P10636-8 (MAPT) S235 Uniprot
P10636-8 (MAPT) S404 Uniprot
P10636-8 (MAPT) S422 Uniprot
P11362 (FGFR1) S777 Uniprot
P13726 (F3) S285 Uniprot
P13726 (F3) S290 Uniprot
P14598 (NCF1) S345 Uniprot
P14598 (NCF1) S348 Uniprot
P15336 (ATF2) T69 Uniprot
P15336 (ATF2) T71 Uniprot
P15336-1 (ATF2) S90 Uniprot
P15923 (TCF3) S139 Uniprot
P16220 (CREB1) S133 Uniprot
P16949 (STMN1) S25 Uniprot
P17181 (IFNAR1) S532 Uniprot
P17275 (JUNB) S79 Uniprot
P17275 (JUNB) T102 Uniprot
P17275 (JUNB) T104 Uniprot
P17302 (GJA1) S279 Uniprot
P17302 (GJA1) S282 Uniprot
P17844 (DDX5) T446 Uniprot
P17844 (DDX5) T564 Uniprot
P17861 (XBP1) S68 Uniprot
P18850 (ATF6) T166 Uniprot
P19419 (ELK1) S383 Uniprot
P19419 (ELK1) S389 Uniprot
P19525 (EIF2AK2) T451 Uniprot
P19634 (SLC9A1) T718 Uniprot
P19634 (SLC9A1) S723 Uniprot
P19634 (SLC9A1) S726 Uniprot
P19634-1 (SLC9A1) S729 Uniprot
P21397 (MAOA) S209 Uniprot
P21462 (FPR1) S342 Uniprot
P22415 (USF1) T153 Uniprot
P28324 (ELK4) S381 Uniprot
P28324 (ELK4) S387 Uniprot
P28698 (MZF1) S256 Uniprot
P28698 (MZF1) S274 Uniprot
P28698 (MZF1) S294 Uniprot
P29353 (SHC1) S36 Uniprot
P29353 (SHC1) S54 Uniprot
P29353 (SHC1) T56 Uniprot
P29353 (SHC1) T386 Uniprot
P30279 (CCND2) T280 Uniprot
P30305 (CDC25B) S323 Uniprot
P30305 (CDC25B) S375 Uniprot
P30307 (CDC25C) S216 Uniprot
P31645 (SLC6A4) T616 Uniprot
P35236 (PTPN7) T66 Uniprot
P35236 (PTPN7) S93 Uniprot
P35236-2 (PTPN7) T105 Uniprot
P35236-2 (PTPN7) S132 Uniprot
P35638-1 (DDIT3) S79 Uniprot
P35638-1 (DDIT3) S82 Uniprot
P36956-3 (SREBF1) S39 Uniprot
P36956 (SREBF1) S63 Uniprot
P36956-3 (SREBF1) T402 Uniprot
P36956 (SREBF1) T426 Uniprot
P38936 (CDKN1A) T57 Uniprot
P38936 (CDKN1A) S130 Uniprot
P40763 (STAT3) S727 Uniprot
P41212 (ETV6) S22 Uniprot
P41212 (ETV6) S257 Uniprot
P41235-5 (HNF4A) S145 Uniprot
P41235 (HNF4A) S167 Uniprot
P41970 (ELK3) S357 Uniprot
P41970 (ELK3) S363 Uniprot
P42224 (STAT1) S727 Uniprot
P42566 (EPS15) S796 Uniprot
P42574 (CASP3) S150 Uniprot
P42677 (RPS27) S27 Uniprot
P47712 (PLA2G4A) S505 Uniprot
P49023 (PXN) S85 Uniprot
P49137-2 (MAPKAPK2) T25 Uniprot
P49137-2 (MAPKAPK2) T206 Uniprot
P49137-2 (MAPKAPK2) T222 Uniprot
P49137 (MAPKAPK2) S272 Uniprot
P49137-1 (MAPKAPK2) T317 Uniprot
P49137-1 (MAPKAPK2) T334 Uniprot
P49841 (GSK3B) S389 Uniprot
P49841 (GSK3B) T390 Uniprot
P49918 (CDKN1C) S146 Uniprot
P52945 (PDX1) S61 Uniprot
P52945 (PDX1) S66 Uniprot
P53667 (LIMK1) S310 Uniprot
P56178 (DLX5) S34 Uniprot
P56178 (DLX5) S217 Uniprot
P61244-2 (MAX) S40 Uniprot
P61244-6 (MAX) S49 Uniprot
P61244-2 (MAX) S135 Uniprot
P61244-1 (MAX) S144 Uniprot
P68431 (HIST1H3J) S11 Uniprot
P68431 (HIST1H3J) S29 Uniprot
P78356 (PIP4K2B) S326 Uniprot
P78536 (ADAM17) T735 Uniprot
P78543 (BTG2) S149 Uniprot
P84022 (SMAD3) S204 Uniprot
P84022 (SMAD3) S208 Uniprot
P84022-1 (SMAD3) S213 Uniprot
Q01844 (EWSR1) T79 Uniprot
Q02078 (MEF2A) S98 Uniprot
Q02078 (MEF2A) T108 Uniprot
Q02078 (MEF2A) S192 Uniprot
Q02078 (MEF2A) S223 Uniprot
Q02078-5 (MEF2A) T304 Uniprot
Q02078-5 (MEF2A) T311 Uniprot
Q02078 (MEF2A) T312 Uniprot
Q02078 (MEF2A) T319 Uniprot
Q02078 (MEF2A) S355 Uniprot
Q02078 (MEF2A) S408 Uniprot
Q02078-5 (MEF2A) S445 Uniprot
Q02078 (MEF2A) S453 Uniprot
Q02078 (MEF2A) S479 Uniprot
Q02078 (MEF2A) S494 Uniprot
Q02156 (PRKCE) S350 Uniprot
Q06330 (RBPJ) T339 Uniprot
Q06413 (MEF2C) T293 Uniprot
Q06413 (MEF2C) T300 Uniprot
Q06413 (MEF2C) S387 Uniprot
Q07666 (KHDRBS1) S58 Uniprot
Q07666 (KHDRBS1) T84 Uniprot
Q07817 (BCL2L1) S62 Uniprot
Q12778 (FOXO1) S416 Uniprot
Q12778 (FOXO1) S432 Uniprot
Q12778 (FOXO1) S470 Uniprot
Q12778 (FOXO1) T478 Uniprot
Q12778 (FOXO1) T560 Uniprot
Q13541 (EIF4EBP1) T37 Uniprot
Q13541 (EIF4EBP1) T46 Uniprot
Q13541 (EIF4EBP1) S65 Uniprot
Q13541 (EIF4EBP1) T70 Uniprot
Q14721 (KCNB1) S805 Uniprot
Q14765 (STAT4) S721 Uniprot
Q14790 (CASP8) S347 Uniprot
Q14934 (NFATC4) S168 Uniprot
Q14934 (NFATC4) S170 Uniprot
Q15046 (KARS) T52 Uniprot
Q15075 (EEA1) T1392 Uniprot
Q15596 (NCOA2) S736 Uniprot
Q15672 (TWIST1) S68 Uniprot
Q15717 (ELAVL1) T118 Uniprot
Q15750 (TAB1) S423 Uniprot
Q15750 (TAB1) T431 Uniprot
Q15750 (TAB1) S438 Uniprot
Q15750 (TAB1) S452 Uniprot
Q15750 (TAB1) S453 Uniprot
Q15750 (TAB1) S456 Uniprot
Q15750 (TAB1) S457 Uniprot
Q15910 (EZH2) T367 Uniprot
Q16539 (MAPK14) T180 Uniprot
Q16539 (MAPK14) Y182 Uniprot
Q86UR1 (NOXA1) S239 Uniprot
Q86UR1 (NOXA1) S282 Uniprot
Q8IW41-1 (MAPKAPK5) T182 Uniprot
Q8NHW3 (MAFA) S14 Uniprot
Q8NHW3 (MAFA) T57 Uniprot
Q8NHW3 (MAFA) T134 Uniprot
Q8TDD2 (SP7) S76 Uniprot
Q8TDD2 (SP7) S80 Uniprot
Q8WYK2-1 (JDP2) T148 Uniprot
Q92945 (KHSRP) T692 Uniprot
Q92993-2 (KAT5) T106 Uniprot
Q92993 (KAT5) T158 Uniprot
Q99460 (PSMD1) T273 Uniprot
Q99626 (CDX2) S283 Uniprot
Q99626 (CDX2) S287 Uniprot
Q99626 (CDX2) S291 Uniprot
Q99626 (CDX2) S295 Uniprot
Q9BR76 (CORO1B) S2 Uniprot
Q9BUB5-2 (MKNK1) T209 Uniprot
Q9BUB5-2 (MKNK1) T214 Uniprot
Q9BUB5 (MKNK1) T250 Uniprot
Q9BUB5 (MKNK1) T255 Uniprot
Q9H1K0 (RBSN) S215 Uniprot
Q9NQU5 (PAK6) S165 Uniprot
Q9NRR4 (DROSHA) S221 Uniprot
Q9NRR4 (DROSHA) S255 Uniprot
Q9NRR4 (DROSHA) T274 Uniprot
Q9NRR4 (DROSHA) S300 Uniprot
Q9NRR4 (DROSHA) S355 Uniprot
Q9UBK2-1 (PPARGC1A) T263 Uniprot
Q9UBK2 (PPARGC1A) S266 Uniprot
Q9UBK2 (PPARGC1A) T299 Uniprot
Q9UIG0 (BAZ1B) S158 Uniprot
Q9UL54-2 (TAOK2) S1031 Uniprot
Q9UQD0 (SCN8A) S553 Uniprot
Q9Y5Y9 (SCN10A) S552 Uniprot
Q9Y698 (CACNG2) T321 Uniprot
Q9Y6Q9 (NCOA3) T24 Uniprot
Q9Y6Q9 (NCOA3) S505 Uniprot
Q9Y6Q9-1 (NCOA3) S543 Uniprot
Q9Y6Q9 (NCOA3) S860 Uniprot
Q9Y6Q9-5 (NCOA3) S867 Uniprot

研究背景

功能:

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by recruiting the transcription machinery. On the other hand, two other kinase targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating EEF2K, which is important for the elongation of mRNA during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, regulate protein synthesis by phosphorylating the initiation factor EIF4E2. MAPK14 interacts also with casein kinase II, leading to its activation through autophosphorylation and further phosphorylation of TP53/p53. In the cytoplasm, the p38 MAPK pathway is an important regulator of protein turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis whose proteasome-mediated degradation is regulated by p38 MAPK phosphorylation. In a similar way, MAPK14 phosphorylates the ubiquitin ligase SIAH2, regulating its activity towards EGLN3. MAPK14 may also inhibit the lysosomal degradation pathway of autophagy by interfering with the intracellular trafficking of the transmembrane protein ATG9. Another function of MAPK14 is to regulate the endocytosis of membrane receptors by different mechanisms that impinge on the small GTPase RAB5A. In addition, clathrin-mediated EGFR internalization induced by inflammatory cytokines and UV irradiation depends on MAPK14-mediated phosphorylation of EGFR itself as well as of RAB5A effectors. Ectodomain shedding of transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17. Such phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-alpha family ligands, which results in the activation of EGFR signaling and cell proliferation. Another p38 MAPK substrate is FGFR1. FGFR1 can be translocated from the extracellular space into the cytosol and nucleus of target cells, and regulates processes such as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation. In the nucleus, many transcription factors are phosphorylated and activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are emerging as important modulators of gene expression by regulating chromatin modifiers and remodelers. The promoters of several genes involved in the inflammatory response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated myeloid cells. This phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking promoters for increased NF-kappa-B recruitment. Phosphorylates CDC25B and CDC25C which is required for binding to 14-3-3 proteins and leads to initiation of a G2 delay after ultraviolet radiation. Phosphorylates TIAR following DNA damage, releasing TIAR from GADD45A mRNA and preventing mRNA degradation. The p38 MAPKs may also have kinase-independent roles, which are thought to be due to the binding to targets in the absence of phosphorylation. Protein O-Glc-N-acylation catalyzed by the OGT is regulated by MAPK14, and, although OGT does not seem to be phosphorylated by MAPK14, their interaction increases upon MAPK14 activation induced by glucose deprivation. This interaction may regulate OGT activity by recruiting it to specific targets such as neurofilament H, stimulating its O-Glc-N-acylation. Required in mid-fetal development for the growth of embryo-derived blood vessels in the labyrinth layer of the placenta. Also plays an essential role in developmental and stress-induced erythropoiesis, through regulation of EPO gene expression. Isoform MXI2 activation is stimulated by mitogens and oxidative stress and only poorly phosphorylates ELK1 and ATF2. Isoform EXIP may play a role in the early onset of apoptosis. Phosphorylates S100A9 at 'Thr-113'.

(Microbial infection) Activated by phosphorylation by M.tuberculosis EsxA in T-cells leading to inhibition of IFN-gamma production; phosphorylation is apparent within 15 minute and is inhibited by kinase-specific inhibitors SB203580 and siRNA.

翻译修饰:

Dually phosphorylated on Thr-180 and Tyr-182 by the MAP2Ks MAP2K3/MKK3, MAP2K4/MKK4 and MAP2K6/MKK6 in response to inflammatory citokines, environmental stress or growth factors, which activates the enzyme. Dual phosphorylation can also be mediated by TAB1-mediated autophosphorylation. TCR engagement in T-cells also leads to Tyr-323 phosphorylation by ZAP70. Dephosphorylated and inactivated by DUPS1, DUSP10 and DUSP16. PPM1D also mediates dephosphorylation and inactivation of MAPK14.

Acetylated at Lys-53 and Lys-152 by KAT2B and EP300. Acetylation at Lys-53 increases the affinity for ATP and enhances kinase activity. Lys-53 and Lys-152 are deacetylated by HDAC3.

Ubiquitinated. Ubiquitination leads to degradation by the proteasome pathway.

细胞定位:

Cytoplasm. Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Brain, heart, placenta, pancreas and skeletal muscle. Expressed to a lesser extent in lung, liver and kidney.

亚基结构:

Component of a signaling complex containing at least AKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13 interacts directly with PKN1, which in turn recruits MAPK14, MAP2K3 and ZAK. Binds to a kinase interaction motif within the protein tyrosine phosphatase, PTPRR (By similarity). This interaction retains MAPK14 in the cytoplasm and prevents nuclear accumulation (By similarity). Interacts with SPAG9 and GADD45A (By similarity). Interacts with CDC25B, CDC25C, DUSP1, DUSP10, DUSP16, NP60, SUPT20H and TAB1. Interacts with casein kinase II subunits CSNK2A1 and CSNK2B. Interacts with PPM1D. Interacts with CDK5RAP3; recruits PPM1D to MAPK14 and may regulate its dephosphorylation.

蛋白家族:

The TXY motif contains the threonine and tyrosine residues whose phosphorylation activates the MAP kinases.

Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. MAP kinase subfamily.

研究领域

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).

· Human Diseases > Infectious diseases: Bacterial > Epithelial cell signaling in Helicobacter pylori infection.

· Human Diseases > Infectious diseases: Bacterial > Shigellosis.

· Human Diseases > Infectious diseases: Bacterial > Salmonella infection.

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Organismal Systems > Circulatory system > Adrenergic signaling in cardiomyocytes.   (View pathway)

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Platelet activation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Th1 and Th2 cell differentiation.   (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Leukocyte transendothelial migration.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Retrograde endocannabinoid signaling.   (View pathway)

· Organismal Systems > Nervous system > Dopaminergic synapse.

· Organismal Systems > Sensory system > Inflammatory mediator regulation of TRP channels.   (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Prolactin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

文献引用

1). Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death & Disease, 2021 (PubMed: 34775496) [IF=9.0]

Application: WB    Species: Human    Sample: HCT116 and DLD-1 cells

Fig. 4 Cetuximab activates p38 MAPK and regulates the Nrf2/HO-1 axis. A Western blot analysis of p-p38, total p38, Nrf2 and HO-1 expression levels in HCT116 and DLD-1 cells incubated with cetuximab (100 μg/ml), SB202190 (1 μM) or cetuximab in combination with SB202190 for 24 h. B HCT116 and DLD-1 cells were treated with cetuximab (100 μg/ml) or RSL3 (1 μM) in the absence or presence of SB202190 (1 μM) for 24 h, and cell viability was assessed by the CCK-8 assay. C The protein levels of Nrf2 and HO-1 in HCT116 and DLD-1 cells or Nrf2 overexpressed HCT116 and DLD-1 cells treated with RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. D HCT116 and DLD-1 cells with overexpression Nrf2 were treated with or without RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. Cell viability was assessed by CCK-8 assays. E The protein level of HO-1 in HCT116 and DLD-1 cells or HO-1 overexpressed HCT116 and DLD-1 cells treated with RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. F HCT116 and DLD-1 cells with overexpression HO-1 were treated with or without RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. Cell viability was assessed by CCK-8 assays. G–H HCT116 and DLD-1 cells were treated with cetuximab (100 μg/ml) or RSL3 (1 μM) with or without t-BHQ (20 μM) or hemin (20 μM) for 24 h, and cell viability was assessed by the CCK-8 assay. **P < 0.01.

2). Protective effect of synbiotic combination of Lactobacillus plantarum SC-5 and olive oil extract tyrosol in a murine model of ulcerative colitis. Journal of translational medicine, 2024 (PubMed: 38528541) [IF=7.4]

3). DADLE promotes motor function recovery by inhibiting cytosolic phospholipase A2 mediated lysosomal membrane permeabilization after spinal cord injury. British journal of pharmacology, 2024 (PubMed: 37766498) [IF=7.3]

4). Profilin1 Regulates Trophoblast Invasion and Macrophage Differentiation. The American Journal of Pathology, 2023 (PubMed: 37164274) [IF=6.0]

5). Integrated Multi-Omics Analysis Reveals Mountain-Cultivated Ginseng Ameliorates Cold-Stimulated Steroid-Resistant Asthma by Regulating Interactions among Microbiota, Genes, and Metabolites. International journal of molecular sciences, 2024 (PubMed: 39201796) [IF=5.6]

Application: WB    Species: Mouse    Sample: lung tissues

Figure 9. Integrated analysis of potential mechanisms and validation of PI3K-Akt/MAPK signaling pathway in the combination of DEX and MCG for the treatment of CSRA. (A) Correlation network of DEGs and DEMs. (B) Heatmap of correlation between DEGs and flora. (C) Heatmap of correlation between DEMs and flora. (D) ROC curve analysis. (E) Flora–gene–metabolite–pathway network. (F) Representative western blotting images. (G) Densitometric quantification of protein expression. Reference: GAPDH. (ns, non-significant; * p < 0.05; ** p < 0.01; *** p < 0.001).

6). Protective effect of remdesivir against pulmonary fibrosis in mice. Frontiers in Pharmacology, 2021 (PubMed: 34512328) [IF=5.6]

Application: WB    Species: Mice    Sample: lung tissues

FIGURE 6 Remdesivir inhibits TGF-β1-induced activation of Smad and non-Smad signaling pathway in lung fibroblasts (A) Luciferase assays of CAGA-NIH3T3 cells. Cells were pretreated with Remdesivir (0–50 μM) for 30 min and then incubated with TGF-β1 (5 ng ml−1) for 24 h, then analyzed with luciferase assay. SB431542 is a TGF-β1/Smad pathway inhibitor and serves as a positive control (B) NIH-3T3 cells were co-treated with TGF-β1 (5 ng ml−1) and Remdesivir (12.5, 25, 50 μM) for 1 h. P-Smad3 and Smad3 were assessed using western blot. GAPDH was used as the internal control (C) PPF cells were co-treated with TGF-β1 (5 ng ml−1) and Remdesivir (12.5, 25, 50 μM) for 1 h. P-Smad3 and Smad3 were assessed using western blot. GAPDH was used as the internal control (D) NIH-3T3 cells were co-treated with TGF-β1 (5 ng ml−1) and Remdesivir (12.5, 25, 50 μM) for 1 h and the phosphorylation levels of P-38, JNK, ERK and Akt were analyzed by Western blot. β-tubulin was used as a loading control in grayscale analysis. Scale bar = 60 μm. Data was presented as the means ± SD, n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

7). Qingyihuaji Formula promotes apoptosis and autophagy through inhibition of MAPK/ERK and PI3K/Akt/mTOR signaling pathway on pancreatic cancer in vivo and in vitro. Journal of Ethnopharmacology, 2023 (PubMed: 36690307) [IF=5.4]

8). Lactobacillus paracasei Jlus66 relieves DSS-induced ulcerative colitis in a murine model by maintaining intestinal barrier integrity, inhibiting inflammation, and improving intestinal microbiota structure. European journal of nutrition, 2024 (PubMed: 38733401) [IF=5.0]

9). Effects and Potential Mechanism of Zhuyu Pill Against Atherosclerosis: Network Pharmacology and Experimental Validation. Drug design, development and therapy, 2023 (PubMed: 36866196) [IF=4.8]

Application: IHC    Species: Mouse    Sample:

Figure 8. Immunohistochemistry results of MAPKp38 and NF-κBp65 (original magnification × 100). (A and B): Representative protein expression of MAPKp38; (C and D): representative protein expression of NF-κBp65. Data are represented as means ± SD; n=3 per group. (**P

Application: WB    Species: Mouse    Sample:

Figure 9. The protein level of MAPK and NF-κB signalling pathway. (A and C): The proteins expression of p38, p-p38, p65, and p-p65; (B and D): representative protein expression of p-p38/p38 and p-p65/p65. Data are represented as means ± SD; n=3 per group. (**P

10). Mechanism of Yishen Chuchan decoction intervention of Parkinson's disease based on network pharmacology and experimental verification. Heliyon, 2024 (PubMed: 39149067) [IF=4.0]

Application: WB    Species: Human    Sample: SH-SY5Y cells

Fig. 7. YCD activated the p38 MAPK pathway in rotenone-treated SH-SY5Y cells. (A) Used core anti-PD targets of YCD to perform KEGG pathway enrichment analysis. (B) The pathway-target network is involved in the process of YCD anti-PD. In the figure, a circle represents 20 major pathways of YCD anti-PD from KEGG analysis; the square represents the targets enriched from major pathways. (C–F) Levels of p38 MAPK and p-p38 were monitored via Western blotting. At least three independent experiments were repeated in each experimental verification. Data are illustrated as mean ± SEM. (C, D). Comparative analysis within the multiple groups was employed via one-way ANOVA, ***p < 0.001 vs. Control + non-medicated serum group; ##p < 0.01 vs. Rotenone + non-medicated serum group. The complete blots are shown in Supplementary Fig. 2. (E, F) The p38 MAPK pathway inhibitor SB203580 (10 μM) was pre-added to the rotenone-treated (2 μM) cells. Comparative analysis within the multiple groups was employed via one-way ANOVA, ****p < 0.0001 vs. Control group; ###p < 0.001, ####p < 0.0001 vs. Rotenone group. The complete blots are shown in Supplementary Fig. 3. Con: contral, ROT: rotenone, NS: non-medicated serum, MS: medicated serum, SB: SB203580.

加载更多

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.